These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

785 related items for PubMed ID: 29212499

  • 1. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J, Chautard E, De Schlichting E, Dupic G, Pereira B, Fogli A, Müller-Barthélémy M, Dalloz P, Khalil T, Dillies AF, Durando X, Godfraind C, Verrelle P.
    Radiat Oncol; 2017 Dec 06; 12(1):197. PubMed ID: 29212499
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.
    Radiat Oncol; 2013 Feb 20; 8():38. PubMed ID: 23425509
    [Abstract] [Full Text] [Related]

  • 3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.
    Neurosurg Focus; 2014 Dec 20; 37(6):E4. PubMed ID: 25434389
    [Abstract] [Full Text] [Related]

  • 4. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V, Klement RJ, Kosmala R, Lisowski D, Flentje M, Polat B.
    Radiat Oncol; 2019 Dec 12; 14(1):227. PubMed ID: 31831026
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L, Chen L, Lv S, Li Q, Chen G, Luo W, Zhou P, Li G.
    Radiat Oncol; 2019 Jun 13; 14(1):104. PubMed ID: 31196126
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):1066-74. PubMed ID: 20932651
    [Abstract] [Full Text] [Related]

  • 7. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
    Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.
    J Neurooncol; 2015 Nov 15; 125(2):359-67. PubMed ID: 26423801
    [Abstract] [Full Text] [Related]

  • 8. Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
    Niyazi M, Schwarz SB, Suchorska B, Belka C.
    Strahlenther Onkol; 2012 Feb 15; 188(2):154-9. PubMed ID: 22231634
    [Abstract] [Full Text] [Related]

  • 9. Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
    Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.
    Int J Radiat Oncol Biol Phys; 2017 Jul 15; 98(4):802-810. PubMed ID: 28602411
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):655-60. PubMed ID: 22483738
    [Abstract] [Full Text] [Related]

  • 13. Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.
    Uto M, Mizowaki T, Ogura K, Arakawa Y, Mineharu Y, Miyamoto S, Hiraoka M.
    Int J Clin Oncol; 2016 Dec 01; 21(6):1023-1029. PubMed ID: 27384182
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):661-7. PubMed ID: 22414280
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.
    Clin Neurol Neurosurg; 2015 May 01; 132():1-8. PubMed ID: 25723791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.